Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents

Journal of Peptide Science

Volumn 18, Issue 4, 2012, Pages 242-251

  Huang, Dawei ^a   Li, Xiaohui ^a   Sun, Lei ^a   Xiu, Zhilong ^a   Nishino, Norikazu ^b  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Anticancer agent; Cyclic tetrapeptide; Docking; Histone deacetylase; Histone deacetylase inhibitor; Molecular dynamics

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; TETRAPEPTIDE; ZINC ION;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CIRCULAR DICHROISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; METAL BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COORDINATION COMPLEXES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS; ZINC;

EID: 84862800182     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2392     Document Type: Article

References (38)

1. Verdin E, Histone Deacetylases-Transcriptional Regulation and other Cellular Functions. Humana Press Inc.: Totowa, NJ, 2006.
2. Drummond DC, Noble GK, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 495-528.
3. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003; 370: 737-749.
4. Voelter-Mahlknecht S, Ho AD, Mahlknecht U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol. Med. 2005; 16: 589-598.
5. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007; 404: 1-13.
6. Bressi JC, Jennings AJ, Skene R, Wu YQ, Melkus R, Jong RD, Shawn O, Grimshaw CE, Navre M, Gangloff AR. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 2010; 20: 3142-3245.
7. Bottomley M, Lo SP, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkuhler C, Gallinari P, Carfi A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory zinc-binding domain. J. Biol. Chem. 2008; 283: 26694-26704.
8. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004; 12: 1325-1334.
9. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002; 1: 287-299.
10. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 2005; 14: 1497-1511.
11. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990; 265: 17174-17179.
12. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 3003-3007.
13. Singh SB, Zink DL, Polishook JD, Dombrowski AW, Darkin-Rattray SJ, Schmatz DM, Goetz MA. Apicidins: novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett. 1996; 37: 8077-8080.
14. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. J. Antibiot. 1994; 47: 301-310.
15. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. 1994; 47: 315-323.
16. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002; 62: 4916-4921.
17. Closse A, Hugenin R. Isolation and structural clarification of chlamydocin. Helv. Chim. Acta 1974; 57: 533-545.
18. De Shepper S, Bruwiere H, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van Heusden J. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J. Pharmacol. Exp. Ther. 2003; 304: 881-888.
19. Gururaj MS, Satoshi A, Tamaki K, Norikazu N, Satoko M, Tomonori GN and Minoru Y. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorgan. Med. Chem. 2007; 15: 7830-7839.
20. Rodriquez M, Terracciano S, Cini E, Settembrini G, Bruno I, Bifulco G, Taddei M, Gomez-Paloma L. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angew. Chem. Int. Ed. 2006; 118: 437-441.
21. Maulucci N, Chini MG, Micco SD, Izzo I, Cafaro E, Russo A, Gallinari P, Paolini C, Nardi MC, Casapullo A, Riccio R, Bifulco G, Riccardis FD. Molecular insights into azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc. 2007; 129: 3007-3012.
22. Li XH, Wang G, Li JX, Xiu ZL, Nishino N. Synthesis and resolution of Boc- l-methylphenylalanines. Chem. J. Chinese U. 2008; 29: 1363-1366.
23. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 2007; 28: 1145-1152.
24. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998; 19: 1639-1662.
25. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 2005; 48: 6936-6947.
26. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995; 8: 127-134.
27. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Hayik S, Roitberg A, Seabra G, Wong KF, Paesani F, Wu X, Brozell S, Tsui V, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafmeister C, Ross WS, Kollman PA. AMBER version 9, University of California: San Francisco, CA, 2006.
28. Wang JM, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000; 21: 1049-1074.
29. Wang J, Wolf RM, Caldwell JW, Kollamn PA, Case DA. Development and testing of a general amber force field. J. Comput. Chem. 2004; 25: 1157-1174.
30. Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J. Comput. Chem. 2000; 21: 132-146.
31. Stote RH, Karplus M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 1995; 23: 12-31.
32. Wang JM, Wang W, Kollman PA. ANTECHAMBER: an accessory software package for molecular mechanical calculations. Abstr. Pap. Am. Chem. Soc. 2001; 222: 403.
33. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983; 79: 926-935.
34. Darden T, York D, Pedersen L. Particle mesh Ewald-an N.Log(N) method for Ewald sums in large systems. J. Chem. Phys. 1993; 98: 10089-10092.
35. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977; 23: 327-341.
36. Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR. Molecular dynamics with coupling to an external bath. J.Chem. Phys. 1984; 81: 3684-3690.
37. Honig B, Nicholls A. Classical electrostatics in biology and chemistry. Science 1995; 268: 1144-1149.
38. Hirashima Y, Kato T, Nishino N, Maeda S, Nishino TG, Yoshida M. Design and synthesis of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. In Proceedings of 29th European Peptide Symposium (Peptides), 2006; 758-759.